Healthcare professionals give pharma company engagements middle-of-the-road reviews in a new survey. (Image: Shutterstock)

January 27, 2023 02:19 PM EST

Marketing

UCB, Novo Nordisk, Gilead rank highest among pharmas for HCP customer experience — survey

Beth Snyder Bulik

Senior Editor

When it comes to customer service to healthcare professionals, pharma companies’ overall average rating is, well, average. Its industry customer experience score of 59 is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

UCB, Novo Nordisk, Gilead rank highest among pharmas for HCP customer experience — survey

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

UCB, No­vo Nordisk, Gilead rank high­est among phar­mas for HCP cus­tomer ex­pe­ri­ence — sur­vey

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

UCB, Novo Nordisk, Gilead rank highest among pharmas for HCP customer experience — survey

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.